Farallon
Farallon is a California-based financial institution that makes investments in public assets.
Business Model:
Revenue: $10M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Farallon Information
Geographic Data
Address: 1 Maritime Plz
City: San Francisco
State: CA
Zip: 94111
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$8B
Social
Metrics
3,143,679Website Global Rank
5,213Website Monthly Traffic
Twitter Followers
Description
Farallon is a California-based financial institution that makes investments in public assets.
Contact Phone:
+14154212132
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2021 | Inivata | Series C | 35M |
| 11/2007 | AdsIt | Series A | 5M |
| 2/2022 | Beta Bionics | Series C | 0 |
| 7/2020 | AUTO1 Group | Convertible Note | 302.7M |
| 7/2018 | Advance Intelligence Group | Series B | 0 |
| 12/2020 | Univercells | Series C | 24.5M |
| 2/2022 | GreenYellow | Convertible Note | 0 |
| 6/2017 | Meituan Bike | Series E | 600M |
| 11/2007 | Youku | Series C | 25M |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 10/2020 | Arena Pharmaceuticals | Post-IPO Equity | 56M |
| 8/2021 | Zepz | Series E | 292M |
| 11/2016 | Hindustan Clean Energy Ltd (HCEL) | Debt Financing | 130M |
| 5/2008 | Sohu.com | Post-IPO Equity | 25M |
| 12/2006 | Youku | Series B | 12M |
| 4/2021 | LUMICKS | Series D | 0 |
| 10/2021 | Better Therapeutics | Post-IPO Equity | 0 |
| 5/2021 | Genapsys | Series D | 0 |
| 1/2021 | FogPharma | Series C | 107M |
| 4/2018 | Manbang Group | Private Equity Round | 0 |
| 6/2008 | Youku | Series D | 40M |
| 4/2020 | CargoX | Series E | 87M |
| 5/2017 | Sea | Series E | 0 |
| 2/2022 | Ada Health | Series B | 0 |
| 4/2014 | Intarcia Therapeutics | Venture Round | 0 |
| 4/2014 | Nexvet | Series B | 31.5M |
| 11/2020 | SomaLogic | Series A | 0 |
| 1/2021 | Ikena Oncology | Series B | 0 |
| 10/2020 | LianBio | Series A | 0 |
| 9/2006 | E-House | Venture Round | 0 |
| 9/2019 | Themis Bioscience | Series D | 44.1M |
| 11/2020 | Imago BioSciences | Series C | 80M |
| 10/2021 | DNA Script | Series C | 0 |
| 8/2020 | Freenome | Series C | 270M |
| 11/2007 | Adsit Media Technology | Series A | 5M |
| 5/2020 | Atento | Post-IPO Equity | - |
| 12/2021 | Freenome | Series D | 300M |
| 11/2012 | Intarcia Therapeutics | Venture Round | 160M |
| 5/2021 | BioTheryX | Series E | 92M |
| 8/2016 | Gojek | Series D | 0 |
| 2/2021 | Orchard Therapeutics | Post-IPO Equity | 150M |
| 10/2020 | Longboard Pharmaceuticals | Series A | 0 |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 1/2020 | Generation Bio | Series C | 110M |
| 7/2019 | Beta Bionics | Series B | 63M |
| 4/2021 | Exscientia | Series D | 225M |
| 3/2021 | EGenesis | Series C | 0 |
| 8/2021 | Tango Therapeutics | Post-IPO Equity | 0 |
| 7/2021 | Point Biopharma | Post-IPO Equity | 0 |
| 5/2021 | Affinia Therapeutics | Series B | 0 |
| 3/2021 | Caribou Biosciences | Series C | 115M |
| 7/2020 | Encoded Therapeutics | Series D | 0 |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 7/2020 | BioAtla | Series D | 0 |
| 1/2021 | Beam Therapeutics | Post-IPO Equity | 260M |
| 7/2020 | VelosBio | Series B | 137M |
| 3/2020 | Pliant Therapeutics | Series C | 0 |
| 4/2021 | Theseus Pharmaceuticals | Series B | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 7/2020 | Annexon Biosciences | Series C | 100M |
| 6/2012 | Rally | Series A | 7.9M |
| 7/2020 | Kesoram Industries | Private Equity Round | - |
| 6/2006 | Heidi Coast Advertising | Series B | - |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
| 3/2006 | Youku | Series A | 3M |
| 2/2022 | GreenYellow | Convertible Note | 0 |
| 2/2022 | Beta Bionics | Series C | 0 |
| 2/2022 | Ada Health | Series B | 0 |
| 1/2022 | Metagenomi | Series B | 0 |
| 12/2021 | Freenome | Series D | 0 |
| 10/2021 | Better Therapeutics | Post-IPO Equity | 0 |
| 10/2021 | DNA Script | Series C | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 9/2021 | SomaLogic | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
